Clinical trial
Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
NCT04552769 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
- Lead sponsor
- Stanford University
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 10, 2020
- Completion date
- January 5, 2025
- Enrollment
- 9 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
anaplastic thyroid cancer, thyroid cancer, undifferentiated thyroid cancer